Membrane-bound IL-15 and CD8 Co-expression in T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cellular therapy (ACT) using T cells and natural killer cells often fails to persist in the tumor microenvironment and loses cytotoxic activity over time, necessitating the development of cells with enhanced persistence and cytotoxic capabilities.
Innovation Solution
The use of nucleic acids encoding specific T cell receptors (TCRs), CD8 polypeptides, and IL-15/IL-15Rα fusion polypeptides to transduce T cells and natural killer cells, enabling them to co-express these proteins and enhance their cytotoxic function and persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional T cells and natural killer cells are used in adoptive cellular therapy, then the therapy can be administered, but the cells fail to persist in the tumor microenvironment and lose cytotoxic activity over time
Solution Approach 1:
The patent combines multiple functional elements (TCR for antigen recognition, CD8 for MHC class I binding and cytotoxic enhancement, and IL-15 for proliferation and persistence) into a single cellular system. This merging of complementary functions creates a synergistic effect that simultaneously improves persistence and maintains cytotoxic activity, directly resolving the contradiction between duration of action and reliability.
Solution Approach 2:
The engineered cells are designed to perform multiple functions simultaneously: TCR-mediated antigen recognition, CD8-mediated MHC class I binding and cytotoxic enhancement, and IL-15-mediated proliferation and persistence. This multi-functionality allows the cells to address both the persistence and cytotoxicity requirements, eliminating the trade-off between these two parameters.
2Reliability
If T cells are engineered to express multiple proteins (TCR, CD8, IL-15), then persistence and cytotoxic activity are enhanced, but the complexity of cell engineering increases
Solution Approach 1:
The cell engineering process is segmented into distinct modular components: TCR expression plasmid, CD8 expression plasmid, and IL-15 expression plasmid. Each component can be independently designed, optimized, and manufactured, then combined through standard transfection protocols. This segmentation reduces the overall complexity by breaking down the multi-protein engineering challenge into manageable, independent modules.
Solution Approach 2:
The patent utilizes standard molecular biology parameters and techniques (plasmid construction, transfection methods, protein expression levels) that are already well-established in the field. By working within existing parameter ranges and methodologies rather than creating entirely new approaches, the engineering complexity is minimized while still achieving the desired multi-functional outcome.
Data Source
AI summary
The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.